For the quarter ending 2025-09-30, NMRA has $177,833K in assets. $45,672K in debts. $129,071K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 129,071 | 124,523 | ||
| Restricted cash | 0 | 0 | ||
| Short-term marketable securities | 42,454 | 93,065 | ||
| Prepaid expenses and other current assets | 5,557 | 5,321 | ||
| Total current assets | 177,082 | 222,909 | ||
| Property and equipment, net | 80 | 87 | ||
| Operating lease right-of-use assets | 474 | 531 | ||
| Other assets | 197 | 298 | ||
| Total assets | 177,833 | 223,825 | ||
| Accounts payable | 549 | 644 | ||
| Accrued liabilities | 24,982 | 20,253 | ||
| Early exercise liability, current portion | 55 | 88 | ||
| Operating lease liabilities, current portion | 256 | 171 | ||
| Total current liabilities | 25,842 | 21,156 | ||
| Long term debt, net | 19,563 | 19,451 | ||
| Operating lease liabilities, noncurrent | 267 | 339 | ||
| Early exercise liability, net of current portion | 0 | 0 | ||
| Total liabilities | 45,672 | 40,946 | ||
| Common stock | 16 | 16 | ||
| Additional paid-in capital | 1,256,835 | 1,250,822 | ||
| Accumulated other comprehensive income | 9 | -15 | ||
| Accumulated deficit | -1,124,699 | -1,067,944 | ||
| Total stockholders' equity | 132,161 | 182,879 | ||
| Total liabilities and stockholders' equity | 177,833 | 223,825 | ||
Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics, Inc. (NMRA)